The Chikungunya virus (CHIKV), transmitted through mosquito bites, has spread to over 110 countries globally. It commonly leads to flu-like symptoms, yet in certain individuals, it provokes long-lasting and intense joint discomfort.
Scientists at the La Jolla Institute for Immunology (LJI) are delving into the mechanisms by which this viral infection induces ongoing joint pain that mirrors the characteristics of rheumatoid arthritis, a well-known autoimmune condition.
In their latest research, LJI researchers provide an essential initial examination of how the human body’s T cells engage with CHIKV. Their findings indicate that CD4+ T cells play a prominent role in combating the virus, inadvertently triggering prolonged inflammation. This insight could shed light on the reasons why a subset of CHIKV-infected individuals experience debilitating joint pain.
“Conditions such as rheumatoid arthritis exhibit precisely these traits,” notes LJI Assistant Professor Daniela Weiskopf, Ph.D., the lead author of the study and a key contributor to LJI’s Center for Vaccine Innovation.
Detailed in a recent publication in Cell Reports Medicine, these results furnish fresh perspectives on the link between certain viral infections and the onset of autoimmune diseases. Furthermore, the study paves the way for innovative treatments aimed at curbing detrimental inflammatory responses.
Examining Immune Responses Against Chikungunya
Weiskopf and her team analyzed immune cells extracted from blood samples of CHIKV patients in Colombia. They evaluated the reactions of these immune cells to short protein fragments, known as peptides, derived from the Chikungunya virus.
This investigative approach pinpointed the primary immune cell types leading the charge against CHIKV. For the first time, the study mapped the specific locations on the virus, termed viral epitopes, that elicited the most robust responses from immune cells.
Unexpectedly, the data highlighted a vigorous reaction from CD4+ T cells to CHIKV. While CD4+ T cells are standard components of the antiviral defense system, they typically operate alongside CD8+ T cells. The latter are often dubbed “killer” T cells due to their aggressive role in neutralizing pathogens.
However, this research demonstrates that CD4+ T cells dominate the response to CHIKV. Notably, these CD4+ T cells persist in the body as memory T cells long after the virus is eradicated.
The analysis revealed that 87 percent of the patients retained detectable CHIKV-specific memory CD4+ T cells in their bloodstream even six years post-infection. By comparison, just 13 percent showed lingering CHIKV-specific memory CD8+ T cells after the same duration.
Weiskopf explains that this distinctive CD4+ T cell pattern aligns more closely with profiles observed in autoimmune disease patients. “As someone focused on infectious diseases, I immediately recognized the resemblance to T-cell behaviors in autoimmunity,” she remarks.
Unusual Characteristics of These T Cells
The heightened activity of CD4+ T cells might account for the observed connection between CHIKV infection and persistent conditions resembling autoimmunity.
“Numerous mouse studies have demonstrated the pathogenic potential of CD4+ T cells,” comments Rimjhim Agarwal, a co-first author of the study, UC San Diego graduate student, and Weiskopf Lab member. “Thus, it was crucial to determine their specific functions in humans battling CHIKV.”
The team conducted a detailed investigation into the precise mechanisms employed by CD4+ T cells against CHIKV. Under normal circumstances, CD4+ T cells exhibit polyfunctionality, secreting a diverse array of signaling molecules to orchestrate a comprehensive immune assault on invaders.
In CHIKV patients suffering from severe joint pain, however, the CD4+ T cells displayed monofunctionality. Remarkably, years after the initial exposure, these cells predominantly released TNF-alpha, a pro-inflammatory cytokine. While TNF-alpha is vital for guiding immune efforts during active infection, it should diminish once the threat is resolved.
This study provides compelling evidence implicating these monofunctional CD4+ T cells as key drivers of the joint pain and sustained inflammation seen after CHIKV infection. Although further exploration is needed, the researchers propose that therapies targeting TNF-alpha inhibition could prove effective in alleviating arthritis-like symptoms in affected patients.
Future Research Directions for Patient Relief
This groundbreaking work opens up numerous avenues for further inquiry. Agarwal is presently investigating a puzzling trend: why women in their forties are disproportionately prone to chronic joint pain following CHIKV infection.
Last year, she secured funding via LJI’s Tullie and Rickey Families SPARK Awards for Innovations in Immunology to probe this gender-specific disparity. Supported particularly by the Rosemary Kraemer Raitt Foundation Trust, her SPARK initiative aims to clarify if CD4+ T cells erroneously target the body’s own tissues during their antiviral campaign against CHIKV.
This research aligns with a growing scientific focus on the interplay between viral infections and autoimmune disorders. Other mosquito-transmitted viruses, like dengue, similarly induce profound and enduring joint issues. Additionally, the rise of “long COVID”—characterized by chronic, autoimmune-resembling inflammation post-SARS-CoV-2 infection—has heightened awareness of these patterns.
“The long-term consequences of SARS-CoV-2 have made it evident to many that viruses can precipitate autoimmune-like conditions,” Agarwal observes. “We have far more questions than solutions at present, but unraveling the virus-autoimmunity nexus remains a top priority.”
The research received support from the National Institutes of Health (Contract No. 75N93019C00065) and the collaborative fund between La Jolla Institute for Immunology (LJI) and Kyowa Kirin (KKUS).
